Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy.
about
Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinomaCrossHub: a tool for multi-way analysis of The Cancer Genome Atlas (TCGA) in the context of gene expression regulation mechanismsPoor prognosis of hexokinase 2 overexpression in solid tumors of digestive system: a meta-analysis.Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2.Mitochondrial and postmitochondrial survival signaling in cancer.Mitochondrial VDAC1-based peptides: Attacking oncogenic properties in glioblastoma.Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis.Mitochondrial VDAC1: A Key Gatekeeper as Potential Therapeutic TargetExpression profiling of mitochondrial voltage-dependent anion channel-1 associated genes predicts recurrence-free survival in human carcinomasMild Alkalization Acutely Triggers the Warburg Effect by Enhancing Hexokinase Activity via Voltage-Dependent Anion Channel BindingVoltage-Dependent Anion Channel 1(VDAC1) Participates the Apoptosis of the Mitochondrial Dysfunction in Desminopathy.Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cellsSystematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic.The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c-Myc and C/EBPβ rather than Enterotoxigenic Bacteroides fragilis InfectionRegulation of VDAC trafficking modulates cell death.Important molecular genetic markers of colorectal cancer.Metabolic enzymes: key modulators of functionality in cancer stem-like cells.Targeting cancer cell mitochondria as a therapeutic approach: recent updates.Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway.The PI3K pathway in B cell metabolismVoltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics.Novel Compounds Targeting the Mitochondrial Protein VDAC1 Inhibit Apoptosis and Protect against Mitochondrial Dysfunction.Viral E6/E7 oncogene and cellular hexokinase 2 expression in HPV-positive cancer cell lines.Upregulation of NETO2 gene in colorectal cancer.Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.Selective Induction of Cancer Cell Death by VDAC1-based Peptides and their Potential Use in Cancer Therapy.FV-429 induces apoptosis and inhibits glycolysis by inhibiting Akt-mediated phosphorylation of hexokinase II in MDA-MB-231 cells.Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer.Targeting Liver Cancer and Associated Pathologies in Mice with a Mitochondrial VDAC1-Based Peptide.Butein Inhibited In Vitro Hexokinase-2-Mediated Tumor Glycolysis in Hepatocellular Carcinoma by Blocking Epidermal Growth Factor Receptor (EGFR).
P2860
Q28072714-4C625F24-26BC-4FFF-B75E-3ADD8CC8B14BQ28392625-51480A1D-6222-4049-A2F6-BC69418F315AQ30234765-08C4828E-7964-467A-8243-372EC1FD1203Q33587154-062E9C42-74D5-4D3E-9B81-48F9AFB50934Q33645577-6F8849DC-1FB4-49F1-B31C-0DE357FC36E1Q33761744-08C24647-EE65-4160-BE96-1657D2710F5EQ33779169-38EFF87D-DD8F-4698-8457-5DBC79D41401Q33854939-8AB6F5A3-3725-417D-9737-40ED9CB3D80CQ34344405-369EACEB-902A-481D-A849-FB761E495EA5Q36091614-D1566218-EFA8-433F-B08E-EC5932BCB576Q36220005-61F5D32C-1DD7-4096-8508-01D70A2C6849Q36255034-1EBD5F23-2ED3-431E-8EC1-22B2F167BBD6Q36371410-2A0C1C90-9C14-4315-A44E-D07C917D54C3Q37084394-ABA2C68C-B53B-46EA-91EC-5E947CFDAEA8Q37492236-DFD0DDC1-3FD7-483B-AA91-31B98F6FAF3DQ37619856-54AC0AB3-C5AA-4A9B-92ED-B5E8C4933B24Q37706766-A167F212-52B5-4AAB-AD5D-A67030CB6847Q38668524-61EB29D6-9553-40B0-B404-4FA71152C743Q38797639-033860C4-A819-4A5D-A808-E018BDF90184Q38919518-89DACB11-5EF5-49B1-A782-B60A5B0E296CQ41173095-08249B2F-4737-4DC1-938D-3B4189234D60Q46478319-4EBBCD6E-D72B-46EE-ABC3-5989DEF2165FQ47104746-5A70942B-C32A-43BD-9725-9D66B870E6A8Q47113925-17733CA5-B7F7-4230-8031-EBA59AFDC7C9Q50105551-A4C89D32-3A1D-498C-9110-CF184C7FE5D5Q52561162-3F444D8D-5EEE-4E6E-866B-587141293701Q53215395-A30837DA-EAC5-488F-8465-441738DCCBE3Q53795029-4FB18357-069E-455A-B27A-31044B915EB1Q54096044-7F86C39D-9D45-4523-8DBB-C26E4477FF7DQ55255442-25A4C527-6D4D-4DE3-87DA-CB01B2C01EF5Q55368961-360AACB0-E6D8-42A0-9213-744F01FCB7D2
P2860
Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting VDAC-bound hexokinas ...... ncomitant anti-cancer therapy.
@en
type
label
Targeting VDAC-bound hexokinas ...... ncomitant anti-cancer therapy.
@en
prefLabel
Targeting VDAC-bound hexokinas ...... ncomitant anti-cancer therapy.
@en
P2093
P2860
P1476
Targeting VDAC-bound hexokinas ...... ncomitant anti-cancer therapy.
@en
P2093
Alexander A Kirpiy
Alexey A Dmitriev
Anna V Kudryavtseva
George S Krasnov
Valentina A Lakunina
P2860
P304
P356
10.1517/14728222.2013.833607
P407
P577
2013-08-28T00:00:00Z